Financing petrochemical projects in China — a sponsor's perspective
Although the nature and function of petrochemical processes and products is often a very unfamiliar subject to the average person working outside the chemicals industry, petrochemicals and the end-products that they make possible are an integral part of modern life. Petrochemicals (which are quite simply chemicals derived from petroleum or natural gas) are critical components of the plastics we use in our home and office, the advanced fibres in the clothes that we wear, and the pharmaceuticals that treat our ailments.
China, due in no small part to heavy demand from its massive manufacturing and textiles sectors, is home to the world’s largest and fastest-growing petrochemicals market. In the last decade, China’s demand for basic petrochemicals and the most commonly used plastics have tripled. The Chinese government has also been paying attention, liberalising rules and policies to encourage the high level of participation from multinational energy and chemicals companies to continue.
The industry is highly capital-intensive as petrochemical facilities often cost hundreds of millions or even billions of US dollars to build and operate. Thus, financing from domestic and international financial institutions are commonplace. Depending on the nature of the project, creditworthiness of the project sponsors and perceived risks to the lenders, such financing may be as simple as a bilateral working capital facility used as a cash flow contingency or as complex as a full scale syndicated project financing involving nearly all of the major domestic Chinese banks and several international lenders…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
Health Alert — Julia Clare v Australian Community Pharmacy Authority; Dr Reid v Medical Council of NSW; and more
DLA Piper has released the 22 December 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The European Court of Justice (CJEU) has handed down a landmark judgment concerning the patentability of stem cells in Europe.
Analysis from The Lawyer
Regulators are ramping up the pressure in the aftermath of recession, leaving firms to compete for compliance and restructuring work
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.